High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
Delphine Réa(Institut Bergonié), Philippe Rousselot(Université Paris-Saclay), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse), Brigitte Dupriez(Centre Hospitalier de Lens), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Sébastien Maury(Assistance Publique – Hôpitaux de Paris), Pascal Turlure(Centre Hospitalier Universitaire de Limoges), M Vigier(Clinique Jules Verne), B Choufi(Centre Jean Perrin), Oumédaly Reman(University of Bern), Mario Ojeda‐Uribe, Emmanuel Raffoux(Inserm), Laurence Legros(Hôpital l'Archet), D. Stéphane(Hôpital Claude Huriez), Xavier Thomas(Hôpital Lyon Sud), Hervé Dombret(University of London Institute in Paris), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Arnaud Pigneux(Centre Hospitalier Universitaire de Bordeaux)
Cited by 77
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k